Articles Tập 67 Số CĐ14-HNKH Hội Hóa sinh Y học Việt Nam 19/09/2026

THE RELATIONSHIP BETWEEN TACROLIMUS CONCENTRATION AND CONCENTRATION/DOSE RATIO AND SEVERAL TOXIC MANIFESTATIONS IN PATIENTS AT 24 MONTHS AFTER KIDNEY TRANSPLANTATION

Vu Quang Hop, Dau Van Hoang, Vu Quang Hop, Vu Viet Nam, Do Manh Ha
DOI: 10.52163/yhc.v67iCD14.6486
0 Views
0 Downloads
Abstract

Objective: To analyze the relationship between concentration and concentration/dose ratio (C/D) of Tacrolimus and certain toxicological manifestations in patients 24 months after kidney transplantation.

Subjects and methods: A descriptive cross-sectional, combined retrospective and prospective study on 97 kidney transplant patients at Military Hospital 103, from March 2023 to June 2026. Information collected included age, gender, hand tremor, concentration, dose of Tacrolimus, plasma glucose, urea, creatinine, AST, and ALT.

Results: A study of 97 patients at 24 months post-kidney transplantation found that 34 patients (35.1%) experienced hand tremor, and 13 patients (13.4%) developed newly diagnosed post-transplant diabetes mellitus (NODAT). However, no statistically significant association was found between these signs and the concentration and concentration-to-dose ratio (C/D) of Tacrolimus, with p > 0.05. Plasma ALT enzyme activity was statistically significantly related to blood Tacrolimus concentration, with p < 0.05.

Conclusion: The study did not find a statistically significant association between Tacrolimus concentration and C/D ratio with hand tremor and NODAT. Tacrolimus concentration significantly increased plasma ALT enzyme activity, with p < 0.05.

Keywords
Tacrolimus, toxicity, kidney transplantation
References
[1]
1. Catherine P. King, Amelia R. Cossart, Nicole M. Isbel.., et al. (2024). The association between tacrolimus exposure and tremor, headach and insomnia in adult kidney transplant recipients: A systematic review. Transplantation Reviews 38 (2024) 100815. Google Scholar
[2]
2. Ioana Adela Ratiu, Florin Bănică, Corina Moisa..,et al. (2025). New-Onset Diabetes After Transplantation in Renal Recipients: A Pilot Comparative Study of Immediate vs. Extended-Release Tacrolimus Formulation. Pharmaceuticals 2025, 18, 1532. Google Scholar
[3]
3. Columbia Transplant British (2021). Mediation guidelines for solid organ transplants. Google Scholar
[4]
4. Genuth, S…et al. (2003). Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 26(11): p. 3160-7. Google Scholar
[5]
5. Park Y, Lee H, Eum SH, Kim HD…et al. (2021). Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation. Front. Immunol. 12:746013. Google Scholar
[6]
6. Riemersma NL, Kremer D, Knobbe TJ… et al. (2023). Tremor, Daily Functioning, and Health Related Quality of Life in Solid Organ Transplant Recipients. Transpl Int 36:10951. Google Scholar
[7]
7. Bzoma B, Konopa J, Chamienia A.. et al . (2025). Post-transplant diabetes mellitus in kidney transplant recipients: A prospective cohort study of risk factors and clinical outcomes. Medicine 104:33(e43981). Google Scholar
[8]
8. C. J. Yates, S. Fourlanos, J. Hjelmesæth…et al. (2012). New-Onset Diabetes After Kidney Transplantation - Changes and Challenges. American Journal of Transplantation; 12: 820–828. Google Scholar
[9]
9. M. Hecking… et al. (2013). Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant 28: 550–566. Google Scholar
[10]
10. D.K. Yadav, Dinesh N. Gera, Manoj R. Gumber et al. (2013). Tacrolimus-Induced Severe Cholestasis Complicating Renal Transplantation. Renal Failure, 35(5): 735–737. Google Scholar
[11]
11. Funda Terzi, Mustafa Kemal Ciftci… et al. (2022). Protective effect of silymarin on tacrolimus-induced kidney and liver toxicity. BMC Complementary Medicine and Therapies 22:231. Google Scholar